Exploring the Therapeutic Potential of JBI-802: A Dual Inhibitor Targeting LSD1 and HDAC6 in Cancer Treatment

3 June 2024
The abstract discusses the role of Lysine Specific Demethylase 1 (LSD1) in various cancers and the potential of inhibiting LSD1 for cancer treatment. It highlights the effectiveness of LSD1 down-regulation in inducing the re-expression of genes that are abnormally silenced, which can lead to the treatment of cancers. The study focuses on the development of a dual inhibitor, JBI-802, which targets both LSD1 and HDAC6/8, and has shown promising results in treating several types of cancer, including acute myelogenous leukaemia (AML), lymphoma, and others.

The methodology involved computational chemistry to design specific inhibitors, followed by in vitro assays to assess LSD1 and HDAC activity. Biomarkers and cell proliferation were evaluated using Western blotting, quantitative PCR, and Alamar blue cytotoxicity assay. In vivo efficacy was tested using xenograft and syngeneic models.

Results indicated that JBI-802 displayed strong potency against LSD1 with high selectivity, and it was particularly effective against AML, CLL, SCLC, sarcoma, and multiple myeloma cell lines. The compound showed significant target engagement and inhibited tumor growth more effectively than single inhibitors. It also demonstrated comparable activity to anti-PD-1/PD-L1 antibodies in a colon cancer model and enhanced tumor growth inhibition when combined with these antibodies. The compound was found to be well-tolerated up to a certain dosage.

The conclusion suggests that dual LSD1-HDAC6/8 inhibitors like JBI-802 could be new and effective therapeutic agents for treating a specific subset of AML and other cancers. The study is progressing towards IND-enabling studies to develop this inhibitor as a clinical candidate. The research was presented at the Annual Meeting of the American Association for Cancer Research in 2020.

How to Use Synapse Database to Search and Analyze Translational Medicine Data?

The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

图片包含 应用程序

描述已自动生成

Click on the image below to go directly to the Translational Medicine search interface.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成